A prospective study on hyperhomocysteinemia as an aggravating factor in chronic venous insufficiency

Rotaru,Maria; Iancu,Gabriela Mariana; Baldovin,Ioana

doi:10.3892/etm.2022.11376

A prospective study on hyperhomocysteinemia as an aggravating factor in chronic venous insufficiency

Authors:
- Maria Rotaru
- Gabriela Mariana Iancu
- Ioana Baldovin
View Affiliations

Affiliations: Department of Dermatology, Faculty of Medicine, ‘Lucian Blaga’ University of Sibiu, 550169 Sibiu, Romania, Clinic of Dermatology, County Emergency Hospital of Sibiu, 550245 Sibiu, Romania
Published online on: May 17, 2022 https://doi.org/10.3892/etm.2022.11376
Article Number: 449

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of hyperhomocysteinemia (HH) in the etiopathogenetics of systemic thrombotic events has been confirmed by numerous studies. However, it has been insufficiently studied as an etiopathogenic factor in chronic venous insufficiency (CVI). The present prospective study included 166 patients with CVI at stages C3‑C6. Homocysteine levels and the inflammatory, metabolic and procoagulant profiles of the patients were determined. High‑performance liquid chromatography was used to determine the homocysteine level. Within the patients with HH, the thromboembolic risk was analyzed. Smoking was determined to represent the most common procoagulant factor (21.67%), whereas in the subgroup of women, abortions represented a procoagulant factor for 31.93%. The metabolic profile was altered in approximately half of all cases (42.77%), whereas proinflammatory status was a contributing factor in 23.50% of the cases. HH was present in 54.22% of the CVI patients, mainly in the moderate HH category (53.01%), mostly linked to venous ulcers, thrombophlebitis and pulmonary thromboembolisms. The highest average values of homocysteine were recorded in patients >75 years old and when the venous disease age was >20 years (15.03 µmol/l). In summary, in the present study, HH was a contributing factor of CVI alongside the chronic inflammation that is well known in CVI, which increased thrombogenic risk, especially in elderly patients with an advanced age of venous disease.

View Figures

View References

1	Nicolaides AN, Allegra C, Bergan J, Bradbury A, Cairols M, Carpentier P, Comerota A, Delis C, Eklof B, Fassiadis N, et al: Management of chronic venous disorders of the lower limbs guidelines according to scientific evidence. Int Angiol. 27:1–59. 2008.PubMed/NCBI
2	Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM and Kirienko AI: Prevalence and risk factors for chronic venous disease in the general Russian population. Eur J Vasc Endovasc Surg. 54:752–758. 2017.PubMed/NCBI View Article : Google Scholar
3	Feodor T, Baila S, Mitea I, Branisteanu D and Vittos O: Epidemiology and clinical characteristics of chronic venous disease in Romania. Exp Ther Med. 17:1097–1105. 2019.PubMed/NCBI View Article : Google Scholar
4	Rabe E, Regnier C, Goron F, Salmat G and Pannier F: The prevalence, disease characteristics and treatment of chronic venous disease: An international web-based study. J Comp Eff Res. 9:1205–1218. 2020.PubMed/NCBI View Article : Google Scholar
5	Patel SK and Surowiec SM: Venous Insufficiency. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2021.
6	Ashorobi D, Ameer MA and Fernandez R: Thrombosis. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2021.
7	Yau JW, Teoh H and Verma S: Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 15(130)2015.PubMed/NCBI View Article : Google Scholar
8	Hotoleanu C: Association between obesity and venous thromboembolism. Med Pharm Rep. 93:162–168. 2020.PubMed/NCBI View Article : Google Scholar
9	Iancu GM, Ocneanu A and Rotaru M: Hydroxyurea-induced superinfected ulcerations: Two case reports and review of the literature. Exp Ther Med. 20(191)2020.PubMed/NCBI View Article : Google Scholar
10	Fortin LJ and Genest J Jr: Measurement of homocyst(e)ine in the prediction of arteriosclerosis. Clin Biochem. 28:155–162. 1995.PubMed/NCBI View Article : Google Scholar
11	Tinelli C, Di Pino A, Ficulle E, Marcelli S and Feligioni M: Hyperhomocysteinemia as a risk factor and potential nutraceutical target for certain pathologies. Front Nutr. 6(49)2019.PubMed/NCBI View Article : Google Scholar
12	Cattaneo M: Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost. 32:716–723. 2006.PubMed/NCBI View Article : Google Scholar
13	Brustolin S, Giugliani R and Felix TM: Genetics of homocysteine metabolism and associated disorders. Bra J Med Biol Res. 4:1–7. 2010.PubMed/NCBI View Article : Google Scholar
14	Son P and Lewis L: Hyperhomocysteinemia. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2020.
15	Zegarra TI and Tadi P: CEAP Classification of Venous Disorders. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2021.
16	Hantusch B: Morphological and functional characteristics of blood and lymphatic vessels. In: Fundamentals of Vascular Biology. Learning Materials in Biosciences. Geiger M (ed). Springer, Cham, pp1-43, 2019.
17	Herouy Y: The role of matrix metalloproteinases (MMPs) and their inhibitors in venous leg ulcer healing. Phebolymphology. 44:31–267. 2004.
18	Barbu A, Neamțu B, Zăhan M, Iancu GM, Bacila C and Mireșan V: Current trends in advanced alginate-based wound dressings for chronic Wounds. J Pers Med. 11(890)2021.PubMed/NCBI View Article : Google Scholar
19	Ali MM, Mahmoud AM, Le Master E, Levitan I and Phillips SA: Role of matrix metalloproteinases and histone deacetylase in oxidative stress-induced degradation of the endothelial glycocalyx. Am J Physiol Heart Circ Physiol. 316:H647–H663. 2019.PubMed/NCBI View Article : Google Scholar
20	Brattström L and Wilcken DE: Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr. 72:315–323. 2000.PubMed/NCBI View Article : Google Scholar
21	Sule AA, Chin TJ and Khien LH: Recurrent unprovoked venous thrombembolism in a young female patient with high levels of homocysteine. Int J Angiol. 21:95–98. 2012.PubMed/NCBI View Article : Google Scholar
22	Bolal M, Ates I, Demir BF, Altay M, Turhan T and Yilmaz N: The relationship between homocysteine and autoimmune subclinical hypothyroidism. Int J Med Biochem. 3:1–7. 2020.
23	Hasan T, Arora R, Bansal AK, Bhattacharya R, Sharma GS and Sigh LR: Disturbed homocysteine metabolism in associated with cancer. Exp Mol Med. 51:1–13. 2019.PubMed/NCBI View Article : Google Scholar
24	Lovčić V, Klobučić M, Bašić-Jukić N and Lovčić P: Is hyperhomocysteinemia approaching traditional risk factors for cardiovascular diseases? Acta Clin Croat. 45 (Suppl 1):S65–S72. 2006.
25	Elian V, Cioca G, Pantea-Stoian A, Dobjanschi C and Serafinceanu C: Metabolic syndrome and chronic kidney disease: Pathogenic, clinical, and therapeutic correlations. In: Proceedings of the 1st International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications (INTERDIAB), Bucharest, 2015.
26	Papatheodorou L and Weiss N: Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxid Redox Signal. 9:1941–1958. 2007.PubMed/NCBI View Article : Google Scholar
27	Esfahani M, Movahedian A, Baranchi M and Goodarzi MT: Adiponectin: An adipokine with protective features against metabolic syndrome. Iran J Basic Med Sci. 18:430–442. 2015.PubMed/NCBI
28	Undas A, Brozek J and Szczeklik A: Homocysteine and thrombosis: From basic science to clinical evidence. Thromb Haemost. 94:907–915. 2005.PubMed/NCBI View Article : Google Scholar
29	Samonakis DN, Oustamanolakis P, Manousou P, Kouroumalis EA and Burroughs AK: Klippel-Trenaunay syndrome, pregnancy and the liver: An unusual interplay. Ann Gastroenterol. 25:365–367. 2012.PubMed/NCBI
30	Rotaru M and Iancu GM: Klippel-Trenaunay-Weber syndrome. Acta Medica Transilvanica. 2:265–267. 2010.
31	den Heijer M, Willems HPJ, Blom HJ, Gerrits WBJ, Cattaneo M, Eichinger S, Rosendaal FR and Bos GMJ: Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood. 109:139–144. 2007.PubMed/NCBI View Article : Google Scholar
32	Ray JG: Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 158:2101–2106. 1998.PubMed/NCBI View Article : Google Scholar
33	Ganguly P and Alam SF: Role of homocysteine in the development of cardiovascular disease. Nutr J. 14(6)2015.PubMed/NCBI View Article : Google Scholar